Information Provided By:
Fly News Breaks for July 24, 2019
SAGE
Jul 24, 2019 | 13:09 EDT
After Sage Therapeutics issued a clinical progress update on some of its depression, neurology, and neuropsychiatry franchise programs, Piper Jaffray analyst Danielle Brill said she thinks its early stage assets, including SAGE-324 in essential tremor and SAGE-718 for disorders with NMDA hypofunction, are "becoming increasingly interesting." Brill, who thinks the readout of the trial of SAGE-217 in major depressive disorder is still the key focus for investors, is confident that trial will be a success and she keeps an Overweight rating on Sage shares.